Intra-Cellular Therapies Inc. - ITCI STOCK NEWS

Intra-Cellular Therapies (Nasdaq: ITCI) has successfully completed a public offering of 9,523,810 shares at $42.00 each, raising approximately $460 million in gross proceeds. The underwriters fully exercised their option for an additional 1,428,571 shares. After deductions, the net proceeds amount to around $433.7 million. The offering was conducted under a shelf registration statement with the SEC. This infusion of capital aims to support the company's ongoing development of therapeutics for central nervous system disorders.

Intra-Cellular Therapies (ITCI) announced the pricing of a public offering of 9,523,810 shares at $42.00 each, totaling $400 million in gross proceeds. The offering will close on January 7, 2022, subject to customary conditions. Underwriters have a 30-day option to purchase an additional 1,428,571 shares. This is part of a shelf registration statement filed with the SEC. The funds raised will support ongoing development of CNS therapeutics, enhancing the company's financial position and growth prospects.

Intra-Cellular Therapies (Nasdaq: ITCI) has initiated a public offering of $400 million in shares of its common stock, with underwriters given a 30-day option to purchase an additional 15% of the shares. The offering is part of a shelf registration statement effective with the SEC. J.P. Morgan, SVB Leerink, and others are acting as joint book-running managers. The offering is subject to market conditions, with no assurance on completion or terms.

Intra-Cellular Therapies (ITCI), a biopharmaceutical company focused on treatments for central nervous system disorders, announced that CEO Sharon Mates, Ph.D., will present at the 40th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for January 10, 2022, at 7:30 AM ET. Investors can access the live and archived webcast through the company's website under the 'Events & Presentations' section. Intra-Cellular Therapies develops innovative therapies based on groundbreaking research to treat complex psychiatric and neurologic conditions.

Intra-Cellular Therapies announced FDA approval for CAPLYTA, the first treatment for depressive episodes associated with bipolar I and II disorder. CAPLYTA is approved as both monotherapy and adjunctive therapy with lithium or valproate. This approval is based on two positive Phase 3 studies showing significant improvements over placebo. Bipolar disorder affects about 11 million adults in the U.S., highlighting a significant unmet medical need. CAPLYTA offers a favorable safety and tolerability profile, making it a crucial treatment option for patients.

Intra-Cellular Therapies (Nasdaq:ITCI) announces the passing of Director Richard Lerner, MD, who contributed significantly to science and medicine. Dr. Lerner served on the board since 2002 and was influential in the company's mission to develop therapies for CNS disorders. His accolades include the Wolf Prize and membership in prestigious scientific academies. The company's leadership, including CEO Sharon Mates, expressed deep sadness and condolences to his family. Intra-Cellular Therapies focuses on innovative treatments for complex psychiatric and neurologic diseases, founded on Nobel Prize-winning research.

Intra-Cellular Therapies reported a remarkable 200% increase in total revenues for Q3 2021, totaling $22.2 million, driven by strong sales of CAPLYTA, which achieved $21.6 million in net product revenues. The company has completed its sales force expansion in preparation for the bipolar depression launch, pending FDA approval with a target date of December 17, 2021. Additionally, CAPLYTA's total prescriptions rose by 15% over the previous quarter. However, the net loss for Q3 grew to $76.9 million compared to $55.2 million a year ago.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) will host a conference call on November 9, 2021, at 8:30 a.m. ET to discuss its financial results for Q3 2021 and provide a corporate update. Investors can access the call via phone or through a live webcast available on the company’s investor relations website. Intra-Cellular Therapies focuses on developing treatments for central nervous system disorders using innovative, research-backed methods.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced a Virtual Event on October 20, 2021, from 1:00 p.m. to 4:00 p.m. ET, focusing on its development programs for lumateperone, ITI-1284, PDE1 inhibitors, and ITI-333. The event will be accessible via a webcast on the company's Investor Relations page. Intra-Cellular Therapies specializes in therapeutics for CNS disorders, leveraging Nobel prize-winning research to develop innovative treatments for psychiatric and neurologic diseases.